These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 526934)

  • 1. Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal Malignancies.
    DeSimone PA; Greco FA; Lessner HF
    Cancer Treat Rep; 1979; 63(11-12):2015-7. PubMed ID: 526934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of anguidine administered weekly.
    Belt RJ; Haas CD; Joseph U; Goodwin W; Moore D; Hoogstraten B
    Cancer Treat Rep; 1979; 63(11-12):1993-5. PubMed ID: 526932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of anguidine (NSC-141537) for adenocarcinoma of the colon or rectum.
    Diggs CH; Scoltock MJ; Wiernik PH
    Cancer Clin Trials; 1978; 1(4):297-9. PubMed ID: 757146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of anguidine (diacetoxyscirpenol, NSC-141537).
    Goodwin W; Haas CD; Fabian C; Heller-Bettinger I; Hoogstraten B
    Cancer; 1978 Jul; 42(1):23-6. PubMed ID: 667795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study.
    Bukowski R; Vaughn C; Bottomley R; Chen T
    Cancer Treat Rep; 1982 Feb; 66(2):381-3. PubMed ID: 7055820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of anguidine in advanced breast cancer.
    Yap HY; Murphy WK; DiStefano A; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1979 May; 63(5):789-91. PubMed ID: 455316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study on bruceantin administered on a weekly schedule.
    Liesmann J; Belt RJ; Haas CD; Hoogstraten B
    Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
    Löffler TM; Freund W; Lipke J; Hausamen TU
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical studies with bruceantin.
    Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
    Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial.
    DeSimone PA; Greco FA; Lessner HF; Bartolucci A
    Am J Clin Oncol; 1986 Jun; 9(3):187-8. PubMed ID: 3728370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic studies of DON.
    Kovach JS; Eagan RT; Powis G; Rubin J; Creagan ET; Moertel CG
    Cancer Treat Rep; 1981; 65(11-12):1031-6. PubMed ID: 7296548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of taxol given as a 3-hour infusion every 21 days.
    Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
    Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Shepherd FA; Latreille J; Paul K; Eisenhauer E
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.